Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2005

View Archived Issues

Schering-Plough highlights first quarter developments

G-207 studied in malignant glioma

NX-1207 shows long-term efficacy in improving the symptoms of BPH

Phase II study investigates ginger for CINV

Dosing begins in phase I trial of Hedgehog antagonist for basal cell carcinoma

Harnal D launched in Japan

Chugai subsidiary renamed

FDA extends action date for SomatoKine NDA

MicroRNAs: potential novel human oncogenes

Further study required for Sativex approval in U.K.

IPI-504 studied in relapsed and relapsed refractory multiple myeloma

Spotlight on PTSD

Phase I results discussed for Sinovac's SARS vaccine

Fast track designation for Laszarin for heart failure in diabetes patients

NIP-004: Novel thrombopoietin mimetic small-molecule compound

Combi-molecule targets Bcr-Abl kinase and damages DNA

Lyrica approved as add-on treatment for partial onset seizures

Zmax single-dose antibiotic receives FDA approval

Long-term effects reported for febuxostat in hyperuricemia and gout

Clazosentan acts as a potent competitive ETA receptor antagonist

NVP-AEW-541 studied for treatment of musculoskeletal tumors

Recent patent discloses novel immunosuppressive agents

Iloprost and bosentan reduce mortality in PPH patients waiting for a transplant

Novel therapeutics for cardiovascular diseases reported in recent patents

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

MCI-196 decreases serum phosphate and cholesterol levels of hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...